Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Lorundrostat demonstrated strong efficacy and safety in the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. These ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...

HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...

and eplerenone is selective to the aldosterone receptor. Although numerous clinical trials have evaluated the efficacy of each drug, no studies have directly compared spironolactone and eplerenone.

Mineralys Therapeutics said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending ...

Drugs that interfere with the renin–angiotensin system can provide renoprotection in patients with diabetic nephropathy, possibly by exerting an antiproteinuric effect. Aldosterone might have a ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

"To develop new treatment models, such as drug treatments ... on top of the kidneys that produce important hormones, such as aldosterone, cortisol and sex hormones. Due to their location, APAs ...